Browse News
Filter News
Found 808,985 articles
-
The Swiss drugmaker raised its full-year guidance Tuesday projecting net sales to grow in the high-single to low double-digit range while reporting better-than-expected first-quarter results.
-
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.
-
Data from the Phase III LUNA 3 study on Tuesday showed that Sanofi’s BTK inhibitor rilzabrutinib significantly improved durable platelet response in patients with chronic immune thrombocytopenia.
-
Bouncing back from a previous rejection, ImmunityBio on Monday secured the FDA’s green light for its IL-15 superagonist Anktiva for non-muscle invasive bladder cancer.
-
The U.S. Supreme Court on Monday indicated that it will not hear Vanda Pharmaceuticals’ petition in its patent case against Teva Pharmaceuticals regarding the former’s sleep-wake disorder drug Hetlioz.
-
The regulator on Monday slapped Abeona Therapeutics with a Complete Response Letter for its investigational cell therapy pz-cel due to chemistry, manufacturing and controls issues.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
4/23/2024
Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials.
-
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
4/23/2024
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA , Inc.
-
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
4/23/2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD).
-
Direct-to-Consumer Genetic Testing Market Rising Rapidly at CAGR 24.43%
4/23/2024
The direct-to-consumer genetic testing market size is expected to be worth around USD 17.35 billion by 2033 and growing at a CAGR of 24.43% from 2024 to 2033, according to Vision Research Reports.
-
SpecialtyVETPATH Taps Proscia For A Full Transformation Of Its Pathology Operations
4/23/2024
SpecialtyVETPATH, a private, pathologist-owned, and pathologist-directed veterinary pathology laboratory, has selected Proscia®, a leading provider of digital and computational pathology solutions
-
Autoimmune Hepatitis Diagnosis and Treatment Market Size Set to Soar USD 19.15 Billion by 2032
4/23/2024
The global autoimmune hepatitis diagnosis and treatment market size is projected to increase from USD 14.03 billion in 2023 to approximately USD 19.15 billion by 2032. This growth, at a CAGR of 3.3% from 2023 to 2032
-
Cell-Based Assays Market Size is Projected USD 38.48 Billion by 2033
4/23/2024
The global cell-based assays market size is calculated at USD 18.25 billion in 2024 and it is increasing around USD 38.48 billion by 2033 with a CAGR of 8.64% from 2024 to 2033. U.S. cell-based assays market size was valued at USD 11.82 billion in 2023.
-
Lipid Nanoparticles (LNPs) CDMO Market to Reach USD 518.2 Million with a CAGR of 14.10% from 2024-2031
4/23/2024
Global Lipid Nanoparticles (LNPs) CDMO Market in terms of revenue was predicted to be worth $182.0 Mn in 2023 and is poised to reach 518.2 Mn by 2031, increasing at a CAGR of 14.10% from 2024 to 2031.
-
Synthetic Biology Market Experiencing Rapid Growth 28.3%
4/23/2024
Precedence Research says, the global synthetic biology market size was evaluated at US$ 16.35 billion in 2023 and is expected to attain around US$ 116.04 billion by 2032, growing at a CAGR of 28.3% from 2023 to 2032.
-
Predictive Biomarkers Market in North America is Expected to Grow with the Highest CAGR – Here’s Why
4/23/2024
Global Predictive Biomarkers Market in terms of revenue is poised to grow at a CAGR of 14.27% from 2024 to 2031.
-
Cell Dissociation Market Hit Robust Growth 13.92% by 2033
4/23/2024
The global cell dissociation market size was evaluated at US$ 550 million in 2023 and is expected to attain around US$ 2,003 million by 2033, growing at a CAGR of 13.92% from 2024 to 2033.